Impact of Sustained Virologic Response on Glycemic Control Among Diabetic Patients With Hepatitis C Virus Related Liver Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03591783

Enrollment

140

Registered

2018-07-19

Start date

2018-08-31

Completion date

2019-12-31

Last updated

2018-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis c

Brief summary

Hepatitis C virus (HCV) is a major cause of chronic liver disease. The World Health Organization has reported that 170 million people are chronically infected with HCV globally. The highest prevalence of HCV infection worldwide exists in Egypt (15%); 90% of infection among Egyptian patients is due to genotype 4

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Chronic HCV infection will be diagnosed based on positive testing for serum HCV RNA and anti-HCV Ab. * Diagnosis of type 2 DM will depend on fasting level of serum glucose more than 126 mg/dl and/or serum level of HbA1c more than 6.5 % on oral hypoglycemic therapy.

Exclusion criteria

* Chronic hepatitis due to causes other than HCV infection * Coinfection with HBV infection * Hepatocellular carcinoma * Child C stage of liver cirrhosis. * Patients with type I diabetes mellitus. * Cardiopulmonary diseases. * Major illness. * Patient receiving corticosteroids. * Patient refused consent.

Design outcomes

Primary

Measure	Time frame	Description
the percentage of patients with glycemic control	3 months	Exploring the impact of achieving SVR by directly acting antiviral drugs on glycemic control among diabetic patients with HCV infection.

Outcome results